Key Insights

Highlights

Success Rate

83% trial completion

Published Results

219 trials with published results (20%)

Research Maturity

640 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.0%

134 terminated out of 1121 trials

Success Rate

82.7%

-3.9% vs benchmark

Late-Stage Pipeline

6%

69 trials in Phase 3/4

Results Transparency

34%

219 of 640 completed with results

Key Signals

219 with results83% success134 terminated

Data Visualizations

Phase Distribution

921Total
Not Applicable (196)
Early P 1 (12)
P 1 (514)
P 2 (130)
P 3 (46)
P 4 (23)

Trial Status

Completed640
Terminated134
Recruiting121
Unknown116
Active Not Recruiting48
Withdrawn25

Trial Success Rate

82.7%

Benchmark: 86.6%

Based on 640 completed trials

Clinical Trials (1121)

Showing 20 of 20 trials
NCT07745816Not ApplicableNot Yet RecruitingPrimary

Effectiveness and Implementation of 'Supportive and Palliative Care Review Kit in Locations Everywhere'

NCT07855666Not ApplicableNot Yet Recruiting

Safety and Efficacy of Ultrasound-Guided Percutaneous Nephrostomy in Oncology Patients

NCT07574541Phase 2Not Yet Recruiting

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT06885697Phase 1Recruiting

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT01443468Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NCT02423057Phase 1CompletedPrimary

Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors

NCT07715903Phase 1Not Yet Recruiting

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

NCT02663297Phase 1Active Not Recruiting

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT07822815Enrolling By InvitationPrimary

Difficult Airway Management in Oncology: An International Delphi Consensus Study (DAMO)

NCT05944237Phase 1RecruitingPrimary

HTL0039732 in Participants With Advanced Solid Tumours

NCT07850700Not Yet RecruitingPrimary

Ambient AI Documentation in Oncology Consultations

NCT05112965Phase 3Active Not RecruitingPrimary

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

NCT01255748RecruitingPrimary

Registry Study for Radiation Therapy Outcomes

NCT04958239Phase 1Active Not RecruitingPrimary

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT06494241Active Not Recruiting

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

NCT05103358Phase 2Completed

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT04449549Phase 2RecruitingPrimary

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

NCT00071045Enrolling By InvitationPrimary

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT04442425Completed

Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain

NCT06884618Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Scroll to load more

Research Network

Activity Timeline